[go: up one dir, main page]

WO1999002132A3 - Use of submicron oil-in-water emulsions with dna vaccines - Google Patents

Use of submicron oil-in-water emulsions with dna vaccines Download PDF

Info

Publication number
WO1999002132A3
WO1999002132A3 PCT/US1998/014310 US9814310W WO9902132A3 WO 1999002132 A3 WO1999002132 A3 WO 1999002132A3 US 9814310 W US9814310 W US 9814310W WO 9902132 A3 WO9902132 A3 WO 9902132A3
Authority
WO
WIPO (PCT)
Prior art keywords
submicron oil
water emulsions
dna vaccines
nucleic acid
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/014310
Other languages
French (fr)
Other versions
WO1999002132A2 (en
Inventor
James E Mccormak
Douglas J Jolly
Nest Gary Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to AU82982/98A priority Critical patent/AU8298298A/en
Priority to CA002295740A priority patent/CA2295740A1/en
Priority to JP50895399A priority patent/JP2002509545A/en
Priority to EP98933312A priority patent/EP1006999A2/en
Publication of WO1999002132A2 publication Critical patent/WO1999002132A2/en
Publication of WO1999002132A3 publication Critical patent/WO1999002132A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of submicron oil-in-water emulsions with nucleic acid immunization techniques is disclosed. The method includes immunization with vaccine compositions containing nucleic acid molecules encoding one or more antigens of interest, as well as administration of a submicron oil-in-water adjuvant, such as MF59. The adjuvant can be administered either before, after or simultaneously with the nucleic acid vaccines.
PCT/US1998/014310 1997-07-08 1998-07-08 Use of submicron oil-in-water emulsions with dna vaccines Ceased WO1999002132A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU82982/98A AU8298298A (en) 1997-07-08 1998-07-08 Use of submicron oil-in-water emulsions with dna vaccines
CA002295740A CA2295740A1 (en) 1997-07-08 1998-07-08 Use of submicron oil-in-water emulsions with dna vaccines
JP50895399A JP2002509545A (en) 1997-07-08 1998-07-08 Use of submicron oil-in-water emulsion with DNA vaccine
EP98933312A EP1006999A2 (en) 1997-07-08 1998-07-08 Use of submicron oil-in-water emulsions with dna vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5194497P 1997-07-08 1997-07-08
US60/051,944 1997-07-08
US5475697P 1997-08-05 1997-08-05
US60/054,756 1997-08-05

Publications (2)

Publication Number Publication Date
WO1999002132A2 WO1999002132A2 (en) 1999-01-21
WO1999002132A3 true WO1999002132A3 (en) 1999-08-12

Family

ID=26729981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014310 Ceased WO1999002132A2 (en) 1997-07-08 1998-07-08 Use of submicron oil-in-water emulsions with dna vaccines

Country Status (5)

Country Link
EP (1) EP1006999A2 (en)
JP (1) JP2002509545A (en)
AU (1) AU8298298A (en)
CA (1) CA2295740A1 (en)
WO (1) WO1999002132A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020677T2 (en) * 1999-02-26 2006-05-04 Chiron Corp., Emeryville MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES
EP1178825B1 (en) 1999-05-13 2011-07-13 Wyeth Holdings Corporation Adjuvant combination formulations
AR045702A1 (en) * 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
JP5759890B2 (en) 2008-03-25 2015-08-05 ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Enhancement of immune response by administration of cationic lipid-DNA complex (CLDC)
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
TW201618806A (en) * 2010-03-29 2016-06-01 諾華公司 Organic compound composition
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
BR112014000235A8 (en) 2011-07-06 2018-03-06 Novartis Ag cationic oil-in-water emulsions
ES2657547T3 (en) 2011-07-06 2018-03-05 Glaxosmithkline Biologicals Sa Oil-in-water emulsions containing nucleic acids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1995033835A1 (en) * 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1995033835A1 (en) * 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE DIALOG MEDLINE 1 January 1900 (1900-01-01), Database accession no. 08554776 *

Also Published As

Publication number Publication date
AU8298298A (en) 1999-02-08
JP2002509545A (en) 2002-03-26
CA2295740A1 (en) 1999-01-21
WO1999002132A2 (en) 1999-01-21
EP1006999A2 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
WO2000020027A3 (en) Methods for therapeutic vaccination
EP1347055A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis
HUP9901901A2 (en) Vaccines against hepatitis c
EP1162272A3 (en) Generation of immune responses to prostate-specific antigen (SPA)
EP1170368A3 (en) Immunization by inoculation of dna transcription unit
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
WO1996040945A3 (en) Nucleic acid respiratory syncytial virus vaccines
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO2000054802A3 (en) Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2003002065A3 (en) Hcv e1e2 vaccine compositions
AU3188297A (en) Liposomal influenza vaccine composition and method
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
WO2001049317A3 (en) Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
WO2001032014A3 (en) Use of salmonella vectors for vaccination against hellicobacter infection
DE69716240D1 (en) NEW METHOD FOR VACCINATION AND VACCINE SUBSTANCES THAT CONTAIN AN EPITOP-CODING NUCLEIC ACID AND AN EPITOP-CONTAINING PEPTIDE
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
WO1999053960A3 (en) Enhancing immune responses to genetic immunization by using a chemokine
WO2003059379A3 (en) Immunogenic carcinoembryonic antigen (cea)
ATE319833T1 (en) VACCINES TO INCREASE IMMUNE RESPONSES AGAINST HERPES SIMPLEX VIRUS
ATE374622T1 (en) GENETIC VACCINES WITH ADJUVANS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2295740

Country of ref document: CA

Ref country code: CA

Ref document number: 2295740

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998933312

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998933312

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998933312

Country of ref document: EP